vanucizumab
mAbexperimentalMulti-specific
Vanucizumab is an experimental humanized monoclonal antibody designed for the treatment of cancer. — Wikipedia
Clinical trial activity
5 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
1
Earliest trial started Oct 31, 2012 (NCT01688206)
Timeline
Indications
Mechanism of action
- Angiopoietin-2INHIBITOR
ANGPT2 inhibitor
- Vascular endothelial growth factor AINHIBITOR
VEGFA inhibitor
VPS51 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- Yes
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaVanucizumab ↗
- ChEMBLCHEMBL3545259 ↗
Also known as
- rg-7221
- ro-5520985
- vanucizumab
- vanucizumab
- vanucizumab
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06770088 | Phase 4 | Jan 10, 2025 | Sun Yat-Sen University |
| NCT02715531 | Phase 1 | Apr 30, 2016 | Roche |
| NCT02665416 | Phase 1 | Jan 25, 2016 | Roche |
| NCT02141295 | Phase 2 | Jun 30, 2014 | Roche |
| NCT01688206 | Phase 1 | Oct 31, 2012 | Roche |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Roche | For profit | 4 | 4 | 2 | 2012 |
| Sun Yat-Sen University | Academic/Hospital | 1 | 1 | 1 | 2025 |
2 organizations
Page 1 / 1